Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutations

Abstract excerpt

BACKGROUND: Somatic mutations in the EGFR gene occur in about 50% of non-small cell lung cancers, with the T790M mutation significantly contributing to secondary resistance against EGFR-TKI drugs. However, EGFR T790M germline mutations rarely occur. CASE PRESENTATION: In this study, we report a case of a lung adenocarcinoma family lineage linked to a germline EGFR T790M mutation. The main subject was diagnosed...

Topics

Join the communities discussing this publication.

• Colorectal Cancer Treatments and Studies
• Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
• Lung Cancer Treatments and Mutations